Vanguard Capital Management’s Atrium Therapeutics RNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.04M Sell
730,026
-805
-0.1% -$9.5K ﹤0.01% 3008
2026
Q2
$9.8M Buy
730,831
+103,962
+17% +$1.36M ﹤0.01% 2829
2026
Q1
$8.38M Buy
+626,869
New +$8.81M ﹤0.01% 2829

Other funds holding RNA

Vanguard Capital Management's RNA Position: Q3 2026 in Review

Vanguard Capital Management reduced its Atrium Therapeutics (RNA) stake by 0.11% in Q3 2026, selling an estimated $9.5K and leaving 730,026 shares worth $6.04M. The position accounts for ﹤0.01% of the portfolio, ranked #3008.

Vanguard Capital Management first reported a position in RNA in Q1 2026 and has held it in 3 quarters since. The position peaked at $9.8M in Q2 2026. 148 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • Vanguard Capital Management held 730,026 shares of Atrium Therapeutics worth $6.04M as of Q3 2026.
  • Vanguard Capital Management sold 805 Atrium Therapeutics shares in Q3 2026, an estimated $9.5K.
  • Atrium Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3008 holding.
  • Vanguard Capital Management first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Atrium Therapeutics position peaked at $9.8M in Q2 2026.
  • 148 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.